TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04054778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar Therapy
Description: Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
Study: NCT05917691

Intervention type: DRUG
Intervention: General anesthetic
Description: Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database).

Intervention type: DEVICE
Intervention: Indeterminate
Description: Devices were indeterminate under the current study design (observational study of a deidentified database).

Intervention type: DEVICE
Intervention: Indeterminate
Description: Devices were indeterminate under the current study design (observational study of a deidentified database).
Study: NCT03282266

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham operation
Description: The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
Study: NCT01129206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
Study: NCT02607137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Information on healthy living style in relation to physical activity
Study: NCT01626651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole (400 mg \[2 x 200 mg\] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
Study: NCT02325050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Study: NCT02279784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freeway PTA
Description: angioplasty with Freeway drug-eluting balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix PTA
Description: angioplasty with Lutonix drug-eluting balloon
Study: NCT00458419

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naloxone versus placebo
Description: 10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous injection of normal saline or naloxone
Description: Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
Study: NCT02748655

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkaline ionized water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Study: NCT02617082

Intervention type: RADIATION
Intervention: partial breast irradiation
Description: The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
Study: NCT02837133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated yoga program
Description: the program as a one-time session for 3 hours as a component of a Stress Management Education program
Study: NCT01007279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROSUVASTATIN
Description: 40 mg before procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSUVASTATIN
Description: 40 mg before procedure
Study: NCT01522079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air stacking manuever
Description: Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
Study: NCT02915926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupational performance coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard OT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard OT
Study: NCT02325050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.
Study: NCT02963584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision aid
Description: The related information about CTO and PCI procedures will be told to the patients thoroughly.
Study: NCT04307472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Nudge
Description: Active choice intervention in the electronic health record and peer comparison messaging on performance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Nudge
Description: Active choice intervention in the electronic health record and peer comparison messaging on performance
Study: NCT01129206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study: NCT03198403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
Study: NCT02695277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure Bipolar System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endocardial Ablation with Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriClip® PRO LAA Exclusion System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial Ablation with Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Endocardial ablation(s)
Study: NCT04331522

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen
Study: NCT02325050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.
Study: NCT04331522

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen
Study: NCT02325050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.
Study: NCT02325050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline.
Study: NCT00238316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg PO daily for 1 year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mg PO daily for one 1 year
Study: NCT02715960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin Capsules
Description: During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
Study: NCT04002154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papilocare vaginal gel
Description: Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papilocare vaginal gel
Description: Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
Study: NCT03546725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking
Description: Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
Study: NCT02261168

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized living protocol
Description: Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
Study: NCT02254668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol with Everolimus (Certican®)
Description: Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol with Mycophenolate mofetil (CellCept®)
Description: Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
Study: NCT04118439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imaginery and Action Observation
Description: A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
Study: NCT04600141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
Study: NCT01104259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03671824

Intervention type: OTHER
Intervention: Measurements
Description: Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.

Intervention type: OTHER
Intervention: Measurements
Description: Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
Study: NCT01374815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Online Advocate
Description: The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Online Advocate
Description: The Online Advocate is a Web-based screening and referral tool for health-related social problems
Study: NCT01345877

Intervention type: PROCEDURE
Group type: OTHER
Intervention: first degree cutaneous burn injury
Description: application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
Study: NCT05528003

Intervention type: PROCEDURE
Intervention: Commercialized single-access port devices
Description: Two kinds of commercialized single-access port devices were used.
Study: NCT01093924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PILI 'Ohana 18-month weight loss maintenance
Description: All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PILI 'Ohana 18-month weight loss maintenance
Description: All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
Study: NCT05127096

Intervention type: DIAGNOSTIC_TEST
Intervention: FirstSight blood test
Description: FirstSight blood test for colorectal cancer screening

Intervention type: DIAGNOSTIC_TEST
Intervention: FirstSight blood test
Description: FirstSight blood test for colorectal cancer screening
Study: NCT03950245

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 and GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 and GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 and GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
Study: NCT03338751

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cognitive testing with HAD (PockeTalker) First
Description: tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cognitive testing with HAD (PockeTalker) First
Description: tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing without HAD First
Description: tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing without HAD First
Description: tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
Study: NCT04600141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin - Therapeutic dosage
Description: Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
Study: NCT00400322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir (Valcyte)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03757494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Stim
Description: Use of Alpha Stim Device
Study: NCT04600141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin - Therapeutic dosage
Description: Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin - Prophylactic dosage
Description: Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin - Prophylactic dosage
Description: Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.